KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Total Non-Current Liabilities (2019 - 2025)

Historic Total Non-Current Liabilities for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $807.9 million.

  • Esperion Therapeutics' Total Non-Current Liabilities rose 1806.49% to $807.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $807.9 million, marking a year-over-year increase of 1806.49%. This contributed to the annual value of $732.5 million for FY2024, which is 7406.69% up from last year.
  • Per Esperion Therapeutics' latest filing, its Total Non-Current Liabilities stood at $807.9 million for Q3 2025, which was up 1806.49% from $773.2 million recorded in Q2 2025.
  • Esperion Therapeutics' Total Non-Current Liabilities' 5-year high stood at $807.9 million during Q3 2025, with a 5-year trough of $332.8 million in Q4 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $371.5 million (2021), whereas its average is $470.4 million.
  • Its Total Non-Current Liabilities has fluctuated over the past 5 years, first surged by 38385.04% in 2021, then crashed by 935.97% in 2022.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Total Non-Current Liabilities stood at $332.8 million in 2021, then grew by 6.03% to $352.9 million in 2022, then rose by 19.26% to $420.8 million in 2023, then surged by 74.07% to $732.5 million in 2024, then rose by 10.29% to $807.9 million in 2025.
  • Its last three reported values are $807.9 million in Q3 2025, $773.2 million for Q2 2025, and $732.5 million during Q4 2024.